Cargando…

Patient-reported barriers to osteoporosis therapy

SUMMARY: We investigated reasons for non-treatment of osteoporosis and discontinuation of osteoporosis therapy. Barriers to treatment include patients’ preference for alternative treatments and a fear of possible side effects. Side effects are a common reason for treatment discontinuation, and they...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindsay, Brianna R., Olufade, Temitope, Bauer, Jennifer, Babrowicz, Jane, Hahn, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851700/
https://www.ncbi.nlm.nih.gov/pubmed/27129487
http://dx.doi.org/10.1007/s11657-016-0272-5
_version_ 1782429847340974080
author Lindsay, Brianna R.
Olufade, Temitope
Bauer, Jennifer
Babrowicz, Jane
Hahn, Rebecca
author_facet Lindsay, Brianna R.
Olufade, Temitope
Bauer, Jennifer
Babrowicz, Jane
Hahn, Rebecca
author_sort Lindsay, Brianna R.
collection PubMed
description SUMMARY: We investigated reasons for non-treatment of osteoporosis and discontinuation of osteoporosis therapy. Barriers to treatment include patients’ preference for alternative treatments and a fear of possible side effects. Side effects are a common reason for treatment discontinuation, and they may be associated with a lack of willingness to restart treatment. PURPOSE/INTRODUCTION: Osteoporosis patients commonly cite treatment-related side effects, or the fear thereof, as a reason for discontinuing or not initiating anti-osteoporosis medications. The purpose of this study was to investigate, from the patient’s perspective, reasons for (i) non-treatment of osteoporosis and (ii) discontinuation of osteoporosis therapy. METHODS: This was an internet-based survey of postmenopausal women in the USA who self-reported having been diagnosed with osteoporosis. Respondents were recruited from consumer research panels and received nominal compensation. RESULTS: Within the surveyed population (N = 1407), 581 patients were currently being treated, 503 had never been treated, and 323 had previously been treated. Among patients never treated for osteoporosis, the highest ranking reasons for non-treatment were the use of alternative treatments such as over-the-counter vitamins/supplements (57.5 % of respondents) and fear of side effects (43.9 %). Among previously treated patients, frequent reasons for discontinuation included the direction of the physician (41.2 % of respondents), concerns about long-term safety (30.3 %), and the experience of side effects (29.8 %). When asked about their willingness to restart their osteoporosis medication, previously treated patients who were not willing (N = 104) to restart had a higher frequency of experiencing side effects (44.2 versus 20.5 % of those willing; P < 0.001). CONCLUSIONS: From the osteoporosis patient’s perspective, barriers to prescription treatment include a preference for alternative, non-prescription treatments and a fear of possible side effects. Side effects are one of the most common reasons for discontinuing osteoporosis medications, and they appear to be associated with a lack of willingness to restart treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11657-016-0272-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4851700
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-48517002016-05-19 Patient-reported barriers to osteoporosis therapy Lindsay, Brianna R. Olufade, Temitope Bauer, Jennifer Babrowicz, Jane Hahn, Rebecca Arch Osteoporos Original Article SUMMARY: We investigated reasons for non-treatment of osteoporosis and discontinuation of osteoporosis therapy. Barriers to treatment include patients’ preference for alternative treatments and a fear of possible side effects. Side effects are a common reason for treatment discontinuation, and they may be associated with a lack of willingness to restart treatment. PURPOSE/INTRODUCTION: Osteoporosis patients commonly cite treatment-related side effects, or the fear thereof, as a reason for discontinuing or not initiating anti-osteoporosis medications. The purpose of this study was to investigate, from the patient’s perspective, reasons for (i) non-treatment of osteoporosis and (ii) discontinuation of osteoporosis therapy. METHODS: This was an internet-based survey of postmenopausal women in the USA who self-reported having been diagnosed with osteoporosis. Respondents were recruited from consumer research panels and received nominal compensation. RESULTS: Within the surveyed population (N = 1407), 581 patients were currently being treated, 503 had never been treated, and 323 had previously been treated. Among patients never treated for osteoporosis, the highest ranking reasons for non-treatment were the use of alternative treatments such as over-the-counter vitamins/supplements (57.5 % of respondents) and fear of side effects (43.9 %). Among previously treated patients, frequent reasons for discontinuation included the direction of the physician (41.2 % of respondents), concerns about long-term safety (30.3 %), and the experience of side effects (29.8 %). When asked about their willingness to restart their osteoporosis medication, previously treated patients who were not willing (N = 104) to restart had a higher frequency of experiencing side effects (44.2 versus 20.5 % of those willing; P < 0.001). CONCLUSIONS: From the osteoporosis patient’s perspective, barriers to prescription treatment include a preference for alternative, non-prescription treatments and a fear of possible side effects. Side effects are one of the most common reasons for discontinuing osteoporosis medications, and they appear to be associated with a lack of willingness to restart treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11657-016-0272-5) contains supplementary material, which is available to authorized users. Springer London 2016-04-29 2016 /pmc/articles/PMC4851700/ /pubmed/27129487 http://dx.doi.org/10.1007/s11657-016-0272-5 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Lindsay, Brianna R.
Olufade, Temitope
Bauer, Jennifer
Babrowicz, Jane
Hahn, Rebecca
Patient-reported barriers to osteoporosis therapy
title Patient-reported barriers to osteoporosis therapy
title_full Patient-reported barriers to osteoporosis therapy
title_fullStr Patient-reported barriers to osteoporosis therapy
title_full_unstemmed Patient-reported barriers to osteoporosis therapy
title_short Patient-reported barriers to osteoporosis therapy
title_sort patient-reported barriers to osteoporosis therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851700/
https://www.ncbi.nlm.nih.gov/pubmed/27129487
http://dx.doi.org/10.1007/s11657-016-0272-5
work_keys_str_mv AT lindsaybriannar patientreportedbarrierstoosteoporosistherapy
AT olufadetemitope patientreportedbarrierstoosteoporosistherapy
AT bauerjennifer patientreportedbarrierstoosteoporosistherapy
AT babrowiczjane patientreportedbarrierstoosteoporosistherapy
AT hahnrebecca patientreportedbarrierstoosteoporosistherapy